DNMT3A as a prognostic marker for OS and RFS in distinct subsets of patients with AML
| . | OS . | RFS . | ||||
|---|---|---|---|---|---|---|
| DNMT3A* . | HR . | P . | DNMT3A* . | HR . | P . | |
| Subset type in total cohort† | ||||||
| CEBPAwt | 94/392 | 1.325 | .046 | 83/316 | 1.414 | .023 |
| FLT3wtNPM1mut | 37/64 | 1.967 | .075 | 34/58 | 1.912 | .089 |
| FLT3ITDNPM1mut | 36/69 | 1.491 | .179 | 32/61 | 1.616 | .133 |
| FLT3wtNPM1wt | 20/235 | 2.167 | .002 | 17/193 | 2.781 | < .001 |
| FLT3wtNPM1wtIDH1wtIDH2wt | 10/203 | 2.830 | .003 | 8/167 | 3.812‡ | |
| FLT3wtNPM1wtCBPAwt | 18/215 | 2.268 | .002 | 15/174 | 2.503 | .002 |
| FLT3wtNPM1wtCBPAwtIDH1wtIDH2wt | 8/184 | 3.987‡ | 6/149 | 3.783‡ | ||
| Normal karyotype | 72/194 | 1.255 | .216 | 67/164 | 1.524 | .033 |
| Intermediate risk group | 85/276 | 1.330 | .073 | 79/236 | 1.530 | .011 |
| Subset type in intermediate risk group§ | ||||||
| CEBPAwt | 83/254 | 1.243 | .179 | 77/215 | 1.373 | .064 |
| FLT3wtNPM1mut | 34/59 | 2.044 | .074 | 31/54 | 2.108 | .063 |
| FLT3ITDNPM1mut | 33/65 | 1.429 | .249 | 31/59 | 1.673 | .117 |
| FLT3wtNPM1wt | 16/117 | 2.097 | .013 | 15/102 | 2.703 | .001 |
| FLT3wtNPM1wtIDH1wtIDH2wt | 7/91 | 2.593‡ | 7/79 | 4.690‡ | ||
| FLT3wtNPM1wtCBPAwt | 14/98 | 2.114 | .017 | 13/84 | 2.181 | .016 |
| FLT3wtNPM1wtCBPAwtIDH1wtIDH2wt | 5/73 | 4.711‡ | 5/62 | 4.616‡ | ||
| . | OS . | RFS . | ||||
|---|---|---|---|---|---|---|
| DNMT3A* . | HR . | P . | DNMT3A* . | HR . | P . | |
| Subset type in total cohort† | ||||||
| CEBPAwt | 94/392 | 1.325 | .046 | 83/316 | 1.414 | .023 |
| FLT3wtNPM1mut | 37/64 | 1.967 | .075 | 34/58 | 1.912 | .089 |
| FLT3ITDNPM1mut | 36/69 | 1.491 | .179 | 32/61 | 1.616 | .133 |
| FLT3wtNPM1wt | 20/235 | 2.167 | .002 | 17/193 | 2.781 | < .001 |
| FLT3wtNPM1wtIDH1wtIDH2wt | 10/203 | 2.830 | .003 | 8/167 | 3.812‡ | |
| FLT3wtNPM1wtCBPAwt | 18/215 | 2.268 | .002 | 15/174 | 2.503 | .002 |
| FLT3wtNPM1wtCBPAwtIDH1wtIDH2wt | 8/184 | 3.987‡ | 6/149 | 3.783‡ | ||
| Normal karyotype | 72/194 | 1.255 | .216 | 67/164 | 1.524 | .033 |
| Intermediate risk group | 85/276 | 1.330 | .073 | 79/236 | 1.530 | .011 |
| Subset type in intermediate risk group§ | ||||||
| CEBPAwt | 83/254 | 1.243 | .179 | 77/215 | 1.373 | .064 |
| FLT3wtNPM1mut | 34/59 | 2.044 | .074 | 31/54 | 2.108 | .063 |
| FLT3ITDNPM1mut | 33/65 | 1.429 | .249 | 31/59 | 1.673 | .117 |
| FLT3wtNPM1wt | 16/117 | 2.097 | .013 | 15/102 | 2.703 | .001 |
| FLT3wtNPM1wtIDH1wtIDH2wt | 7/91 | 2.593‡ | 7/79 | 4.690‡ | ||
| FLT3wtNPM1wtCBPAwt | 14/98 | 2.114 | .017 | 13/84 | 2.181 | .016 |
| FLT3wtNPM1wtCBPAwtIDH1wtIDH2wt | 5/73 | 4.711‡ | 5/62 | 4.616‡ | ||
The overall survival (OS) and relapse-free survival (RFS) were determined in the distinct subgroups indicated.
HR indicates hazard ratio; CEBPAwt, no CEBPADM; and FLT3wt, no FLT3ITD.
DNMT3A means the number of mutants detected among the total number of patients that were present in the indicated subgroup.
Subgroups were defined within the total cohort of 415 patients < 60 years of age with AMLs and excluding the APLs.
Numbers were too low for reliable statistical analysis.
Patients < 60 years with cytogenetically intermediate risk were studied.